Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events

Nature Immunology

Volumn 17, Issue 2, 2016, Pages 204-213

  Sobolev, Olga ^a,b,c   Binda, Elisa ^a,c,d   O'Farrell, Sean ^a,b,c   Lorenc, Anna ^c   Pradines, Joel ^e   Huang, Yongqing ^e   Duffner, Jay ^e   Schulz, Reiner ^c,f   Cason, John ^f   Zambon, Maria ^g   Malim, Michael H ^c,f   Peakman, Mark ^a,c   Cope, Andrew ^c,f   Capila, Ishan ^e   Kaundinya, Ganesh V ^e   Hayday, Adrian C ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e Momenta Pharmaceuticals Inc   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; AUTOANTIBODY; CYTOKINE; IMMUNOLOGICAL ADJUVANT; TRANSCRIPTOME; VIRUS ANTIBODY;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; BLOOD; BONE MARROW CELL; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOPHENOTYPING; INFLUENZA A VIRUS (H1N1); INNATE IMMUNITY; INSOMNIA; LYMPHOID CELL; MALE; MYALGIA; NORMAL HUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PRURITUS; SOMNOLENCE; VACCINATION; ADOLESCENT; B LYMPHOCYTE; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; CLUSTER ANALYSIS; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MYELOID CELLS; PHENOTYPE; TIME FACTORS; TRANSCRIPTOME; VACCINATION; YOUNG ADULT;

EID: 84955127051     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3328     Document Type: Article

References (40)

1. Agnandji, S. T. et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe-preliminary report. N. Engl. J. Med. doi:10. 1056/NEJMoa1502924 (1 April 2015).
2. Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
3. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445 (2011).
4. Czirr, E. & Wyss-Coray, T. The immunology of neurodegeneration. J. Clin. Invest. 122, 1156-1163 (2012).
5. Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
6. Pulendran, B. Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc. Natl. Acad. Sci. USA 111, 12300-12306 (2014).
7. Duffy, D. et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 40, 436-450 (2014).
8. Tsang, J. S. et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 157, 499-513 (2014).
9. Callahan, M. K., Wolchok, J. D. & Allison, J. P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37, 473-484 (2010).
10. Oswald, M. et al. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. Arthritis Rheumatol. 67, 344-351 (2015).
11. Chen, R. T. et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12, 542-550 (1994).
12. Grohskopf, L. A. et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 influenza season. MMWR 63, 691-697 (2014).
13. Furman, D. et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol. Syst. Biol. 9, 659 (2013).
14. Zimmer, S. M. & Burke, D. S. Historical perspective-emergence of influenza A (H1N1) viruses. N. Engl. J. Med. 361, 279-285 (2009).
15. Nakaya, H. I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786-795 (2011).
16. Bucasas, K. L. et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J. Infect. Dis. 203, 921-929 (2011).
17. Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195-204 (2014).
18. Roman, F. et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18, 835-843 (2011).
19. Morel, S. et al. Adjuvant system AS03 containing ?-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461-2473 (2011).
20. Strid, J., Sobolev, O., Zafirova, B., Polic, B. & Hayday, A. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science 334, 1293-1297 (2011).
21. Wencker, M. et al. Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness. Nat. Immunol. 15, 80-87 (2014).
22. Brandes, M. et al. Cross-presenting human T cells induce robust CD8+ T cell responses. Proc. Natl. Acad. Sci. USA 106, 2307-2312 (2009).
23. Bolognese, J. A., Schnitzer, T. J. & Ehrich, E. W. Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthritis Cartilage 11, 499-507 (2003).
24. Obermoser, G. et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 38, 831-844 (2013).
25. Franco, L. M. et al. Integrative genomic analysis of the human immune response to influenza vaccination. eLife 2, e00299 (2013).
26. Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413-424 (2006).
27. Montecino-Rodriguez, E., Berent-Maoz, B. & Dorshkind, K. Causes, consequences, and reversal of immune system aging. J. Clin. Invest. 123, 958-965 (2013).
28. Jiang, N. et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci. Transl. Med. 5, 171ra19 (2013).
29. Whitney, A. R. et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. USA 100, 1896-1901 (2003).
30. Nakaya, H. I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786-795 (2011).
31. Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125 (2008).
32. Yang, M., Rui, K., Wang, S. & Lu, L. Regulatory B cells in autoimmune diseases. Cell. Mol. Immunol. 10, 122-132 (2013).
33. Engel, P., Gómez-Puerta, J. A., Ramos-Casals, M., Lozano, F. & Bosch, X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol. Rev. 63, 127-156 (2011).
34. Jackson, L. A. et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: A randomized clinical trial. JAMA 314, 237-246 (2015).
35. Neves, P. C. da C., Matos, D. C. de S., Marcovistz, R. & Galler, R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 27, 5543-5549 (2009).
36. Miller, J. D. et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710-722 (2008).
37. Bentebibel, S.-E. et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci. Transl. Med. 5, 176ra32 (2013).
38. Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37-47 (2015).
39. Shin, M. S. et al. Maintenance of CMV-specific CD8+ T cell responses and the relationship of IL-27 to IFN-? levels with aging. Cytokine 61, 485-490 (2013).
40. Fülöp, T., Larbi, A. & Pawelec, G. Human T cell aging and the impact of persistent viral infections. Front. Immunol. 4, 271 (2013).